Back to top
more

Myriad Genetics (MYGN)

(Delayed Data from NSDQ)

$17.57 USD

17.57
1,452,620

-0.04 (-0.23%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $17.55 -0.02 (-0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Myriad Genetics (MYGN) Expands in MRD Testing With New Collab

by Zacks Equity Research

Myriad Genetics (MYGN) inks an agreement with Personalis to cross-license patent estates covering tumor-informed approaches to detect minimal residual disease. The idea is to broaden patient access to the benefits of MRD testing.

Myriad Genetics (MYGN) Advances in MRD Space With New Patent

by Zacks Equity Research

Myriad Genetics (MYGN) achieves a second foundational patent bolstering the MRD assay development.

Myriad Genetics (MYGN) and GSK Unite to Boost HRD Testing

by Zacks Equity Research

Myriad Genetics (MYGN) collaborates with GSK to improve access to HRD diagnostic testing for HGSOC patients.

Myriad Genetics (MYGN) Banks on Innovation Amid Macro Woes

by Zacks Equity Research

Myriad Genetics (MYGN) continues to enhance its customer targeting, digital marketing and overall operating model to drive commercial leverage in 2024 and beyond.

Myriad (MYGN) Down 5.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

QIAGEN (QGEN) Develops Test for Research and CDx Application

by Zacks Equity Research

QIAGEN's (QGEN) next-generation sequencing test aims to aid personalized medicine research in solid tumor types, including ovarian cancer, and improve decentralized testing capabilities.

Myriad Genetics (MYGN) Posts Narrower-Than-Estimate Loss in Q1

by Zacks Equity Research

Myriad Genetics (MYGN) first-quarter average revenue per test across its product portfolio benefited from expanded coverage and ongoing efforts in revenue cycle management.

Myriad (MYGN) Reports Q1 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for Myriad (MYGN) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Myriad Genetics (MYGN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myriad (MYGN) delivered earnings and revenue surprises of 90.91% and 4.55%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 19.51% and 16.40%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Stoke Therapeutics, Inc. (STOK) Q1 Earnings Expected to Decline

by Zacks Equity Research

Stoke Therapeutics (STOK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Myriad Genetics (MYGN) Report Negative Q1 Earnings? What You Should Know

by Zacks Equity Research

Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Atossa (ATOS) Reports Positive Results From EVANGELINE Study

by Zacks Equity Research

Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.

Myriad Genetics (MYGN) Announces Favorable Research Results

by Zacks Equity Research

Myriad Genetics' (MYGN) latest positive initial study outcome is likely to improve clinical outcomes and reduce overall healthcare costs.

Here's Why You Should Retain Myriad Genetics (MYGN) Stock Now

by Zacks Equity Research

Investors are optimistic about Myriad Genetics' (MYGN) strong solvency position and improvement in testing volume.

Novavax (NVAX) Down 3.2% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Novavax (NVAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Why Is Myriad (MYGN) Down 1% Since Last Earnings Report?

by Zacks Equity Research

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Myriad Genetics (MYGN) Wins Foundational Patent for MRD Assay

by Zacks Equity Research

Myriad Genetics' (MYGN) new patent grant is likely to bolster the ability to deliver a tumor-informed, high-definition MRD assay to the market.

Myriad Genetics (MYGN) to Evaluate MRD Testing With New Pact

by Zacks Equity Research

Myriad Genetics' (MYGN) MRD test is uniquely capable of detecting ctDNA at the lowest levels of detection, which is essential for a pan-cancer investigation.

Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Myriad Genetics (MYGN) Q4 Earnings Top Estimate, Margins Down

by Zacks Equity Research

Myriad Genetics (MYGN) registers a strong testing volume improvement across all its businesses in the fourth quarter of 2023.

Myriad (MYGN) Reports Q4 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Myriad Genetics (MYGN) Tops Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Myriad (MYGN) delivered earnings and revenue surprises of 100% and 1.17%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Wall Street's Insights Into Key Metrics Ahead of Myriad (MYGN) Q4 Earnings

by Zacks Equity Research

Get a deeper insight into the potential performance of Myriad (MYGN) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Quest Diagnostics (DGX) Advances in Cancer Research With New Deal

by Zacks Equity Research

Quest Diagnostics' (DGX) subsidiary Haystack Oncology collaborates with TriSalus Life Sciences to improve therapeutic options for aggressive forms of cancer.